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of the Italian health care system. The following direct medical
care costs were considered: drug costs (cost to the hospital at the
dosage range reported in the SPC), administration costs (medical
devices for deferoxamine, hospital cost), laboratory assessments
(cost of laboratory exams from SPC, using hospital reimburse-
ment tariff). All costs are expressed as Euros (year 2007 values).
We considered the patients with beta thalassaemia major that
live in the Veneto region. RESULTS: According to the Regional
Rare Diseases Register, in Veneto 170 patients are affected
by thalassaemia. 153 are eligible for deferasirox treatment.
Switching all patients from deferoxamine (estimated annual
costs: €734,808–1,327,797), to deferasirox (estimated annual
costs: €3,615,382–5,575,618), would cause an expenditure
increase of €2,881,074–4,247,823/year. From drug utilization
data, it is estimated that about 15 patients with beta-talassemia
are treated with deferiprone. In this scenario, the budget impact
of switching all patients to deferasirox would be €2,858,547–
4,283,481. CONCLUSIONS: Besides the advantage of the oral
administration instead of continous subcutaneous infusion by
pump, the impact of deferasirox on the regional budget is rel-
evant. Alternative scenarios may take into account switching to
the new drug only patients subgroups (e.g., patients who do not
respond to deferoxamine) or patients for whom quality of life is
strongly affected by the infusion pump.
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OBJECTIVES: The budget impact of introducing OROS® hydro-
morphone once-daily, a novel therapy for treating patients with
severe chronic cancer and non-cancer pain, was determined in
the German health care system. METHODS: The perspective of
the social health insurance over a one-year time horizon was
adopted. An Excel® based hypothetical budget impact model
calculating the cost consequences of using strong opioids (WHO
step III) was developed. The model accounts for the costs of
opioids, breakthrough pain and adverse events. Patient numbers
are calculated using epidemiological data from the literature;
adverse event rates are based on literature. Comparators
included sustained-release (SR) morphine (twice-daily),
controlled-release (CR) oxycodone (twice-daily), hydromor-
phone (twice-daily), transdermal fentanyl and transdermal
buprenorphine. Initial prescription share of OROS® hydromor-
phone was 2.4% (October 2007 MAT). This share was hypo-
thetically extended to 8%. It was assumed that this increase in
prescription of OROS® hydromorphone is gained by switching
patients from their previous medication to OROS® hydromor-
phone (proportionally to the prescription share of the compara-
tor at start). Titration and maintenance dosing schemes taken
from previous analyses are used to model the switch. Morphine
equivalence of hydromorphone was chosen according to SmPC.
RESULTS: The number of patients treated was estimated to be
882,347 per year. The model predicted that the introduction of
OROS® HM would lower the per patient drug cost from €684.28
to €679.52 (2008 public prices). The model also predicts that
as the use of OROS® HM increases, the total budget for
strong opioids decreases. If the prescription share of OROS® HM
increased to 8% the total budget for strong opioids would
decrease by €4,199,327. CONCLUSIONS: Our analysis suggests
that under current circumstances the use of OROS® hydromor-
phone to treat patients with severe chronic pain will reduce the
overall budget spent on strong opioids.
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OBJECTIVES: Study costs of carrying out a genetic screening
programme per 100.000 individuals from the Spanish population
under 30 years of age for Hereditary Hemochromatosis (HH),
based on the calculated penetrance of HH in the South-West
Healthcare Area 11 of Madrid, and the published prevalence of
the HH genotype in Spain. METHODS: Retrospective cross-
sectional study of HFE genotyping requests from a subpopula-
tion in South West Madrid pre-screened for high ferritin values,
between January 2000 and June 2006. Based on our population’s
genotype and phenotype, clinical penetrance was calculated in a
previous study. Costs, extracted from a Spanish Medical Cost
database (SOYKOS), involved in treatment of HH-associated
diseases, biochemical testing, genetic testing, treatment of phe-
notypical HH patients and follow up were analysed to compare
the costs for genetic screening versus no screening. RESULTS:
From our data, for the main HH-associated diseases, we have
previously calculated a clinical penetrance, for HH genotype, in
the population studied, of 1.11%, compared to 0.08% for those
with wild-type HFE genotype. The main HH-associated patholo-
gies considered are hepatopathy, diabetes and arthropathy. Cost
for genetic testing of 100,000 Spanish individuals under 30 years
of, biochemical follow up of those with HH genotype, and treat-
ment of those with HH genotype and phenotype amounts to
€1,808,353.29, equivalent to €1433.49/case with HH geno-
type detected and €129,168.09 per phenotypical case with HH
genotype detected. Treatment of HH-associated pathologies,
if no other preventive intervention is undertaken (biochemical
monitoring, preventive phlebotomy treatment), would cost
€407,043.70. CONCLUSIONS: The extremely low penetrance
of HH-associated pathologies related to the HH genotype, sug-
gests that a genetic screening programme for the population
proposed is not economically justiﬁed for the Spanish National
Healthcare System. However, this does not exclude genetic
screening of ﬁrst degree relatives of HH patients and their
subsequent biochemical follow-up which could prove to be
appropriate.
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OBJECTIVES: NICE has recommended etanercept for use in
patients with severe chronic plaque psoriasis, deﬁned as a Pso-
riasis Area and Severity Index (PASI) of 10 or more and a
Dermatology Life Quality Index (DLQI) of more than 10. This
study assessed the cost-effectiveness of intermittent therapy with
etanercept 25 mg twice weekly (biw) or 50 mg biw compared
with no systemic therapy (NST) in patients with less severe
disease. METHODS: An economic model was constructed to
estimate the incremental cost per quality adjusted life year
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